ArticleAnnals of surgery2026
Prolonged Time to Surgery in Patients With Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.
Article in Annals of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Detecting residual disease after neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: The prospective multicentre preSINO trial.The British journal of surgery · 2025Trial
- Association between surgical timing and postoperative outcome in patients with residual esophageal cancer after neoadjuvant chemoradiotherapy.Journal of gastrointestinal oncology · 2026Article
- Active surveillance for esophageal cancer after clinically complete response: relevant considerations of the SANO-trial.Journal of thoracic disease · 2026Article
- Optimal timing of surgery in head and neck squamous cell carcinoma after neoadjuvant immunochemotherapy.Frontiers in oncology · 2026Article
- Prolonged time interval from neoadjuvant immunotherapy combined with chemotherapy to surgery is related to unimproved pathological response and poor survival prognosis for esophageal squamous cell carcinoma.BMC gastroenterology · 2025Article
- Organ-Sparing Approach after Neoadjuvant Treatment in Oesophageal Cancer.Digestive surgery · 2025Review
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate whether prolonged time to surgery negatively affects survival, pathologic outcome, or postoperative complications in patients with histologically proven residual disease after neoadjuvant chemoradiotherapy (nCRT) for locally advanced esophageal cancer.
backgroundHistorically, the standard time to surgery (TTS) has been 6 to 8 weeks after completion of nCRT. The effect of prolonged TTS is gaining interest, with contradicting results on survival and surgical morbidity. It can be hypothesized that, in patients with residual disease 6 weeks after completion of nCRT, prolonged TTS might be associated with worse survival and higher morbidity.
methodsPatients with locally advanced esophageal cancer who had biopsy-proven residual disease 6 weeks after nCRT and underwent surgery, were categorized according to interval to surgery (TTS>12w vs TTS≤12w). The primary outcome of this study was overall survival. Secondary outcomes were disease-free survival, surgical outcomes, pathologic outcomes, and postoperative complications. Multivariable Cox regression was used for comparing survival and logistic regression for other outcomes, adjusted for the confounders age, cT, cN, Charlson comorbidity index, weight loss during nCRT, and WHO performance score after completion of nCRT.
resultsForty patients were included for TTS>12w and 127 for TTS≤12w. TTS>12w was associated with better overall survival [adjusted hazard ratio (aHR) 0.46, 95% CI: 0.24-0.90], and disease-free survival (aHR 0.48, 95% CI: 0.24-0.94), but also with more postoperative respiratory complications (aOR 3.66, 95% CI: 1.52-9.59). Other outcomes were comparable between both groups.
conclusionsProlonged TTS in patients with histologically proven residual disease after completion of nCRT for esophageal cancer did not have a negative effect on overall and disease-free survival, but patients did have a higher risk for postoperative respiratory complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.